SCHEMBL5451179

SCHEMBL5451179

COC(=O)c1sc(S(=O)(=O)Cl)cc1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
NPSR1 Q6W5P4 2/20 0.41
PPARG P37231 1/20 0.41
NCOA2 Q15596 1/20 0.41
NCOA1 Q15788 1/20 0.41
NCOA3 Q9Y6Q9 1/20 0.41
ALDH1A1 P00352 5/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 3/20 0.40
TSHR P16473 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALOX15 P16050 1/20 0.39
RAB9A P51151 3/20 0.38
MEN1 O00255 2/20 0.37
NPC1 O15118 2/20 0.37
CASP3 P42574 1/20 0.37
SENP8 Q96LD8 1/20 0.37
SENP7 Q9BQF6 1/20 0.37
SENP6 Q9GZR1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3719251 0.86 LMNA (0.41) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL21963229 0.81 LMNA (0.41) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL20681197 0.78 LMNA (0.44) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL26281532 0.77 KMT2A (0.44) LMNANPSR1ALDH1A1MAPTKMT2A
SCHEMBL2027674 0.76 MAPT (0.47) LMNANPSR1ALDH1A1MAPTKMT2A
SCHEMBL19505825 0.75 LMNA (0.44) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL14302878 0.73 LMNA (0.42) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL21962166 0.73 NPSR1 (0.42) LMNANPSR1PPARGNCOA2NCOA1
SCHEMBL21152503 0.73 MAPT (0.44) LMNAALDH1A1MAPTKMT2ATSHR
SCHEMBL12272115 0.73 MAPT (0.57) LMNAALDH1A1MAPTKMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101370811-A Imidazopyrazine compounds as protein kinase inhibitors SCHERING CORP (US) 2009-02-18 CN disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 US disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 US disclosed
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors SCHERING CORPORATION 2007-05-24 US disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed
US-20070105864-A1 Methods for inhibiting protein kinases SCHERING CORPORATION 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070117804-A1 Imidazopyrazines as protein kinase inhibitors CHEK1, CHEK2, CDKN1A LMNA 2229/4885NPSR1 4025/4885PPARG 1571/4885
US-20070105864-A1 Methods for inhibiting protein kinases PIM1, PIM2, PIM3 LMNA 1462/4885NPSR1 4607/4885PPARG 3391/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.